查看購物車
  • Simplified Chinese
  • English
  • Japanese
微量殘存疾病檢測的全球市場：按產品、技術、應用、最終用戶、地區分類 - 到 2029 年的預測
市場調查報告書
商品編碼
1614459

微量殘存疾病檢測的全球市場：按產品、技術、應用、最終用戶、地區分類 - 到 2029 年的預測

Minimal Residual Disease Market by Product (Kits, Instruments), Technology (PCR, NGS), Application (Leukemia, Lymphoma, Multiple Myeloma, Solid Tumors), End User (Hospitals, Diagnostic Labs, Research Institutes), & Region - Global Forecast to 2029
出版日期: | 出版商: MarketsandMarkets | 英文 246 Pages | 訂單完成後即時交付

價格

微量殘存疾病(MRD) 檢測的市場規模預計將從 2024 年的 14.3 億美元成長到 2029 年的 25.5 億美元，預測期內複合年成長率為 12.2%。

全球癌症控制計畫資金和津貼的增加已成為 MRD 檢測市場的關鍵成長要素。各國政府和國際組織，包括世界衛生組織和全球基金，目前正在投入大量資源來解決日益沉重的癌症負擔，特別是在早期發現和預防方面。這些資金被用於改善診斷設施的使用，特別是在醫療基礎設施通常薄弱的高負擔地區。也鼓勵對照顧患者的醫療保健專業人員進行培訓，以實現癌症的準確診斷和適當管理。除此之外，研究津貼和國際合作也使得將癌症檢測納入常規醫療服務成為可能。因此，增加資金可以實現 MRD 檢測並加強全球癌症控制工作。這正在推動全球微量殘存疾病檢測市場的成長。

調查範圍
調查年份 2022-2029
基準年 2023年
預測期 2024-2029
考慮單位 金額（美元）
部分 按產品、技術、應用、最終用戶、地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東/非洲、海灣合作理事會國家

MRD 檢測市場依產品分為檢測試劑套件/試劑和設備。預計檢測試劑套件和試劑在預測期內的複合年成長率最高。主要促進因素之一是測試的高精度。高風險族群接受這些檢測繼續支持需求的成長。包括世界衛生組織在內的多個國際衛生組織的有利監管核准和建議也有助於提高採用率。除了這些因素之外，癌症研究資金的增加和診斷學的進步也推動了 MRD 檢測市場中檢測套組細分市場的快速成長。

依應用分類，微量殘存疾病檢測市場分為骨髓惡性腫瘤、固態腫瘤和其他應用。 2021年，骨髓惡性腫瘤佔最大佔有率。促成此細分市場成長的因素是白血病、淋巴瘤及其類型的發生率增加以及對這些疾病患者持續監測的認知。

全球 MRD 檢測市場分為北美、歐洲、亞太地區、拉丁美洲、中東和非洲。值得注意的是，亞太地區預計將在預測期內實現最高成長。包括印度和中國在內的亞太地區是結核病高發生率地區，因此癌症篩檢和管理至關重要。各國政府和國際組織增加的資金以及根除癌症的宣傳活動也改善了亞洲及太平洋地區獲得診斷和醫療基礎設施的機會。當地社區和醫療保健專業人員對早期發現癌症的必要性的認知不斷提高，也大大增加了對進一步檢測的需求。 MRD 檢測市場區隔市場的另一個主要成長要素是醫療保健成本的上升，這也是由法律規範推動的。所有這些因素都在推動亞太地區 MRD 檢測市場的成長。

本報告檢視了全球微量殘存疾病檢測市場，並按產品、技術、應用、最終用戶、地區和進入市場的公司概況總結了趨勢。

目錄

第1章簡介

第2章調查方法

第3章執行摘要

第 4 章重要考察

第5章市場概況

  • 介紹
  • 市場動態
  • 價格分析
  • 專利分析
  • 價值鏈分析
  • 供應鏈分析
  • 貿易分析
  • 生態系分析
  • 波特五力分析
  • 主要相關人員和採購標準
  • 監管分析
  • 技術分析
  • 2023-2024年重大會議和活動
  • 影響客戶業務的趨勢/干擾
  • 投資金籌措場景
  • 案例研究分析
  • 人工智慧/產生人工智慧對微量殘存疾病檢測市場的影響

第6章微量殘存疾病檢測市場（分產品）

  • 介紹
  • 檢測試劑套件/試劑
  • 裝置

第7章微量殘存疾病檢測市場（依技術分）

  • 介紹
  • 聚合酵素鏈鎖反應
  • 次世代定序
  • 流式細胞技術
  • 其他

第8章微量殘存疾病檢測市場（依用途）

  • 介紹
  • 造血系統惡性
  • 固態腫瘤
  • 多發性骨髓瘤
  • 其他

第9章微量殘存疾病檢測市場（依最終用戶）

  • 介紹
  • 醫院和專科診所
  • 診斷實驗室
  • 學術研究所
  • 其他

第10章微量殘存疾病檢測市場（分地區）

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 中國
    • 日本
    • 印度
    • 其他
  • 拉丁美洲
    • 增加私人和公共投資以刺激市場
    • 拉丁美洲宏觀經濟展望
  • 中東/非洲
    • 增加研究經費以推動市場
    • 中東和非洲宏觀經濟前景
  • 海灣合作理事會國家
    • 對先進醫療基礎設施的關注和不斷增加的研究經費推動海灣合作理事會市場
    • 海灣合作理事會國家的宏觀經濟前景

第11章競爭格局

  • 概述
  • 主要參與企業的策略/優勢
  • 2019-2023年收益分析
  • 2023 年市場佔有率分析
  • 企業評估矩陣：主要參與企業，2023
  • 企業評估矩陣：Start-Ups/小型企業，2023 年
  • 公司評價及財務指標
  • 品牌/產品比較
  • 競爭場景

第12章 公司簡介

  • 主要參與企業
    • F. HOFFMANN-LA ROCHE AG
    • LABORATORY CORPORATION OF AMERICA HOLDINGS
    • GUARDANT HEALTH, INC.
    • SYSMEX CORPORATION
    • NEOGENOMICS LABORATORIES
    • MOLECULARMD（A SUBSIDIARY OF ICON PLC）
    • ADAPTIVE BIOTECHNOLOGIES
    • ARCHERDX（INVITAE CORPORATION）
    • BIO-RAD LABORATORIES, INC.
    • NATERA, INC.
  • 其他公司
    • OPKO HEALTH, INC.
    • GENETRON HEALTH
    • QUEST DIAGNOSTICS, INC.
    • ASURAGEN, INC.
    • INVIVOSCRIBE, INC.
    • ARUP LABORATORIES INC.
    • MISSION BIO, INC.
    • CERGENTIS BV

第13章附錄

Product Code: MD 8516

The MRD testing market will rise in value from estimated USD 1.43 Billion in 2024 to USD 2.55 Billion in 2029, at a CAGR of 12.2% over the forecast period. Increased funding and grants for cancer control programs across the globe have emerged as an important growth factor in the MRD testing market. Substantial funding is now being committed by governments and international bodies, including WHO and the Global Fund, to address the increasing burden of cancer, especially in terms of early detection and prevention. These funds are being channelled into increasing access to diagnostic facilities, especially in high-burden regions where the healthcare infrastructure is generally weak. The availability of funds also encourages the training of healthcare professionals who work with a patient to accurately diagnose and properly manage cases of cancer. Apart from that, research grants and international collaborations are also enabling cancer testing integration into routine health care services. Thus, this growing funding is rendering MRD tests available and enhancing the efforts to control cancer globally. This, in turn, is fuelling the growth of the global minimal residual disease testing market.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD)
SegmentsProduct, technology, application, end user, and region
Regions coveredNorth America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries

"MRD Assay Kits & Reagents segment is expected to have the fastest growth rate in the MRD testing market, by product, during the forecast period."

The MRD testing market is segmented into assay kits & reagents, and instruments based on product. Assay kits & reagents are projected to account for the highest CAGR during the forecast period. One major driving factor is its higher accuracy of tests. Growing penetration of these tests in high-risk populations, continue to support increased demand. Favourable regulatory approvals and recommendations by various international health bodies, including the WHO, have also helped increase their adoption. Along with such factors, rising funding for research in cancer and advancements in diagnostics are also driving the high growth of the test kits segment in the MRD testing market.

"Haematological malignancies segment accounted for the highest growth rate in the MRD testing market, by application, during the forecast period."

Based on application, the minimal residual disease testing market is segmented into hematological malignancies, solid tumors, and other applications. In 2021, the hematological malignancies application segment accounted for the largest share. Factors contributing to the growth of this segment are increasing incidences of leukemia, lymphoma and their types and awareness about continuous monitoring of patients with these diseases.

"Asia Pacific: The fastest-growing region in MRD testing market."

The worldwide market for MRD testing is categorized into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. Notably, the Asia Pacific region is anticipated to experience the most substantial growth in the forecast period. The Asia Pacific region bears a high burden of tuberculosis, such as in India and China, which record a high incidence rate and thereby drives the need for essential cancer screening and management. Growth in government and international organization funding and campaigns against cancer has also led to better access to diagnostics and healthcare infrastructure in Asia Pacific. Awareness among the communities and among healthcare workers regarding the need for early detection of cancer has also been significantly increasing the demand for further testing. Another major growth driver of this segment in the MRD testing market is the increasing healthcare expenditure, along with supportive regulatory frameworks. All these factors propel increased growth of the MRD testing market in the Asia Pacific region.

The break-up of the profile of primary participants in the MRD testing market:

  • By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
  • By Designation: Managers - 30%, D-level - 50%, and Others - 20%
  • By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Others - 4%

The key players in this market are are F. Hoffmann-La Roche Ltd. (Switzerland), Labcorp Inc. (US), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US), ArcherDX, Inc. (US), Asuragen Inc. (US), Arup Laboratories Inc. (US), Bio-Rad Laboratories, Inc. (US), Cergentis B.V. (Netherlands), Molecular MD (ICON plc) (Ireland), Invivoscribe, Inc. (US), Mission Bio, Inc. (US), Natera, Inc. (US), Opko Health, Inc. (US), Quest Diagnostics (US), and Genetron Health (China).

Research Coverage:

This research report categorizes the MRD testing market by product (assay kits & reagents, instruments), by technology (PCR, NGS, flow cytometry, and other applications), by application (hematological malignancies, solid tumors, multiple myeloma, and other applications), by end user (diagnostic laboratories, hospitals & clinics, academic & research institutes, and other end users), and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa and GCC Countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the MRD testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the MRD testing market. Competitive analysis of upcoming startups in the MRD testing market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall MRD testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

  • Analysis of key drivers (rising incidence of cancer, and increased funding and grants for cancer control programs), opportunities (Growth opportunities in emerging economies), restraints (Unfavorable reimbursement scenario), and challenges (changing regulatory landscape and operational barriers and labor shortage) influencing the growth of the MRD testing market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the MRD testing market.
  • Market Development: Comprehensive information about lucrative markets - the report analyses the MRD testing market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the MRD testing market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like F. Hoffmann-La Roche Ltd. (Switzerland), Labcorp Inc. (US), Guardant Health (US), Sysmex Corporation (Japan), NeoGenomics Laboratories, Inc. (US), Adaptive Biotechnologies Corporation (US).

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
  • 2.2 RESEARCH APPROACH
    • 2.2.1 SECONDARY DATA
      • 2.2.1.1 Key data from secondary sources
    • 2.2.2 PRIMARY DATA
      • 2.2.2.1 Primary sources
      • 2.2.2.2 Key data from primary sources
      • 2.2.2.3 Key industry insights
      • 2.2.2.4 Breakdown of primary interviews
  • 2.3 MARKET SIZE ESTIMATION
    • 2.3.1 BOTTOM-UP APPROACH
      • 2.3.1.1 Approach 1: Company revenue estimation
      • 2.3.1.2 Approach 2: Presentations of companies and primary interviews
      • 2.3.1.3 Growth forecast
      • 2.3.1.4 CAGR projections
    • 2.3.2 TOP-DOWN APPROACH
  • 2.4 MARKET BREAKDOWN & DATA TRIANGULATION
  • 2.5 MARKET SHARE ESTIMATION
  • 2.6 STUDY ASSUMPTIONS
  • 2.7 GROWTH RATE ASSUMPTIONS
  • 2.8 RESEARCH LIMITATIONS
  • 2.9 RISK ASSESSMENT
    • 2.9.1 RISK ASSESSMENT: MINIMAL RESIDUAL DISEASE TESTING MARKET

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 MINIMAL RESIDUAL DISEASE TESTING MARKET OVERVIEW
  • 4.2 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY PRODUCT, 2024 VS. 2029
  • 4.3 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY TECHNOLOGY, 2024 VS. 2029
  • 4.4 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY APPLICATION, 2024 VS. 2029
  • 4.5 MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY END USER, 2024 VS. 2029
  • 4.6 MINIMAL RESIDUAL DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Rising incidence of hematological malignancies
      • 5.2.1.2 Increasing collaborations and partnerships between pharmaceutical companies and product manufacturers
      • 5.2.1.3 Increasing cancer awareness initiatives by global health organizations
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Complex regulatory frameworks delaying approvals of new molecular diagnostics tests
      • 5.2.2.2 High cost of minimal residual disease testing kits
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Growth opportunities in emerging countries
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Unclear reimbursement scenario and policies for patients
  • 5.3 PRICING ANALYSIS
    • 5.3.1 INDICATIVE PRICING TREND OF KEY PLAYERS, BY PRODUCT & REGION
  • 5.4 PATENT ANALYSIS
    • 5.4.1 LIST OF MAJOR PATENTS
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT DATA
    • 5.7.2 EXPORT DATA
  • 5.8 ECOSYSTEM ANALYSIS
    • 5.8.1 ROLE IN ECOSYSTEM
  • 5.9 PORTER'S FIVE FORCES ANALYSIS
    • 5.9.1 THREAT OF NEW ENTRANTS
    • 5.9.2 THREAT OF SUBSTITUTES
    • 5.9.3 BARGAINING POWER OF BUYERS
    • 5.9.4 BARGAINING POWER OF SUPPLIERS
    • 5.9.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.10.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.10.2 BUYING CRITERIA
  • 5.11 REGULATORY ANALYSIS
    • 5.11.1 REGULATORY LANDSCAPE
      • 5.11.1.1 North America
        • 5.11.1.1.1 US
        • 5.11.1.1.2 Canada
      • 5.11.1.2 Europe
      • 5.11.1.3 Asia Pacific
        • 5.11.1.3.1 China
        • 5.11.1.3.2 Japan
      • 5.11.1.4 Latin America
        • 5.11.1.4.1 Brazil
        • 5.11.1.4.2 Mexico
      • 5.11.1.5 Middle East
      • 5.11.1.6 Africa
    • 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12 TECHNOLOGY ANALYSIS
    • 5.12.1 KEY TECHNOLOGIES
      • 5.12.1.1 PCR and NGS
    • 5.12.2 ADJACENT TECHNOLOGIES
      • 5.12.2.1 Digital PCR
  • 5.13 KEY CONFERENCES & EVENTS IN 2023-2024
  • 5.14 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.15 INVESTMENT & FUNDING SCENARIO
  • 5.16 CASE STUDY ANALYSIS
  • 5.17 IMPACT OF AI/GEN AI ON MINIMAL RESIDUAL DISEASE TESTING MARKET

6 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 ASSAY KITS & REAGENTS
    • 6.2.1 INCREASING AWARENESS ABOUT EARLY DISEASE DETECTION AND PREVENTIVE HEALTHCARE TO PROPEL MARKET
  • 6.3 INSTRUMENTS
    • 6.3.1 RISING NEED FOR FASTER AND MORE ACCURATE TEST RESULTS TO DRIVE MARKET GROWTH

7 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 POLYMERASE CHAIN REACTION
    • 7.2.1 COST BENEFITS OF PCR TECHNOLOGY TO DRIVE ADOPTION
  • 7.3 NEXT-GENERATION SEQUENCING
    • 7.3.1 HIGH SENSITIVITY AND ECONOMIC BENEFITS TO SUPPORT ADOPTION
  • 7.4 FLOW CYTOMETRY
    • 7.4.1 GROWING INCIDENCE AND PREVALENCE OF CANCER TO PROPEL MARKET GROWTH
  • 7.5 OTHER TECHNOLOGIES

8 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
  • 8.2 HEMATOLOGICAL MALIGNANCIES
    • 8.2.1 LEUKEMIA
      • 8.2.1.1 Myeloid leukemia
        • 8.2.1.1.1 High prevalence of AML in adults to support growth
      • 8.2.1.2 Lymphocytic leukemia
        • 8.2.1.2.1 High incidence of ALL in children to drive market
      • 8.2.1.3 Other leukemias
    • 8.2.2 LYMPHOMA
      • 8.2.2.1 Non-Hodgkin lymphoma
        • 8.2.2.1.1 Growing consumption of medications that suppress immune system to drive growth
      • 8.2.2.2 Hodgkin lymphoma
        • 8.2.2.2.1 Growing incidence of Hodgkin lymphoma to propel demand for MRD testing
  • 8.3 SOLID TUMORS
    • 8.3.1 ABILITY OF MRD TO ASSESS TREATMENT RESPONSE TO FUEL GROWTH
  • 8.4 MULTIPLE MYELOMA
    • 8.4.1 RISING INCIDENCE OF MULTIPLE MYELOMAS TO DRIVE MARKET
  • 8.5 OTHER APPLICATIONS

9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER

  • 9.1 INTRODUCTION
  • 9.2 HOSPITALS & SPECIALTY CLINICS
    • 9.2.1 INCREASING NUMBER OF PATIENTS VISITING HOSPITALS TO DRIVE GROWTH
  • 9.3 DIAGNOSTIC LABORATORIES
    • 9.3.1 ROBUST INFRASTRUCTURE AND SPECIALIZED TESTING CAPABILITIES TO SUPPORT GROWTH
  • 9.4 ACADEMIC & RESEARCH INSTITUTES
    • 9.4.1 INCREASING RESEARCH ACTIVITIES TO BOOST MARKET
  • 9.5 OTHER END USERS

10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION

  • 10.1 INTRODUCTION
  • 10.2 NORTH AMERICA
    • 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 10.2.2 US
      • 10.2.2.1 Increasing prevalence of cancer to drive market
    • 10.2.3 CANADA
      • 10.2.3.1 Availability of various cancer screening programs to support market growth
  • 10.3 EUROPE
    • 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 10.3.2 GERMANY
      • 10.3.2.1 Government support for research funding to support MRD testing market
    • 10.3.3 UK
      • 10.3.3.1 Increasing number of diagnostic laboratories to propel market growth
    • 10.3.4 FRANCE
      • 10.3.4.1 Rising R&D expenditure in France to drive market
    • 10.3.5 ITALY
      • 10.3.5.1 Favorable funding scenario to drive market
    • 10.3.6 SPAIN
      • 10.3.6.1 Consolidation of laboratories in Spain to support market growth
    • 10.3.7 REST OF EUROPE
  • 10.4 ASIA PACIFIC
    • 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 10.4.2 CHINA
      • 10.4.2.1 Growing public access to advanced healthcare facilities to drive market
    • 10.4.3 JAPAN
      • 10.4.3.1 Universal healthcare reimbursement policy to support market growth
    • 10.4.4 INDIA
      • 10.4.4.1 Increasing private and public investments in healthcare system to drive market
    • 10.4.5 REST OF ASIA PACIFIC
  • 10.5 LATIN AMERICA
    • 10.5.1 INCREASING PRIVATE AND PUBLIC INVESTMENTS TO DRIVE MARKET
    • 10.5.2 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 INCREASING FUNDING IN RESEARCH TO DRIVE MARKET
    • 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 10.7 GCC COUNTRIES
    • 10.7.1 RISING FOCUS ON ADVANCED HEALTH INFRASTRUCTURE AND FUNDING IN RESEARCH TO DRIVE GCC MARKET
    • 10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN
    • 11.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
  • 11.3 REVENUE ANALYSIS, 2019-2023
  • 11.4 MARKET SHARE ANALYSIS, 2023
  • 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
    • 11.5.1 LIST OF EVALUATED VENDORS
    • 11.5.2 STARS
    • 11.5.3 EMERGING LEADERS
    • 11.5.4 PERVASIVE PLAYERS
    • 11.5.5 PARTICIPANTS
    • 11.5.6 COMPANY FOOTPRINT: KEY PLAYERS, 2023
      • 11.5.6.1 Company footprint
      • 11.5.6.2 Product footprint
      • 11.5.6.3 Technology footprint
      • 11.5.6.4 Application footprint
      • 11.5.6.5 Region footprint
  • 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 RESPONSIVE COMPANIES
    • 11.6.3 DYNAMIC COMPANIES
    • 11.6.4 STARTING BLOCKS
    • 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
  • 11.7 COMPANY VALUATION & FINANCIAL METRICS
  • 11.8 BRAND/PRODUCT COMPARISON
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PRODUCT LAUNCHES
    • 11.9.2 DEALS

12 COMPANY PROFILES

  • 12.1 KEY PLAYERS
    • 12.1.1 F. HOFFMANN-LA ROCHE AG
      • 12.1.1.1 Business overview
      • 12.1.1.2 Products offered
      • 12.1.1.3 Recent developments
        • 12.1.1.3.1 Product launches
      • 12.1.1.4 MnM view
        • 12.1.1.4.1 Right to win
        • 12.1.1.4.2 Strategic choices
        • 12.1.1.4.3 Weaknesses & competitive threats
    • 12.1.2 LABORATORY CORPORATION OF AMERICA HOLDINGS
      • 12.1.2.1 Business overview
      • 12.1.2.2 Products offered
      • 12.1.2.3 Recent developments
        • 12.1.2.3.1 Deals
      • 12.1.2.4 MnM view
        • 12.1.2.4.1 Right to win
        • 12.1.2.4.2 Strategic choices
        • 12.1.2.4.3 Weaknesses & competitive threats
    • 12.1.3 GUARDANT HEALTH, INC.
      • 12.1.3.1 Business overview
      • 12.1.3.2 Products offered
      • 12.1.3.3 Recent developments
        • 12.1.3.3.1 Product launches & approvals
        • 12.1.3.3.2 Deals
      • 12.1.3.4 MnM view
        • 12.1.3.4.1 Right to win
        • 12.1.3.4.2 Strategic choices
        • 12.1.3.4.3 Weaknesses & competitive threats
    • 12.1.4 SYSMEX CORPORATION
      • 12.1.4.1 Business overview
      • 12.1.4.2 Products offered
      • 12.1.4.3 Recent developments
        • 12.1.4.3.1 Product launches
      • 12.1.4.4 MnM view
        • 12.1.4.4.1 Right to win
        • 12.1.4.4.2 Strategic choices
        • 12.1.4.4.3 Weaknesses & competitive threats
    • 12.1.5 NEOGENOMICS LABORATORIES
      • 12.1.5.1 Business overview
      • 12.1.5.2 Products offered
      • 12.1.5.3 Recent developments
        • 12.1.5.3.1 Deals
      • 12.1.5.4 MnM view
        • 12.1.5.4.1 Right to win
        • 12.1.5.4.2 Strategic choices
        • 12.1.5.4.3 Weaknesses & competitive threats
    • 12.1.6 MOLECULARMD (A SUBSIDIARY OF ICON PLC)
      • 12.1.6.1 Business overview
      • 12.1.6.2 Products offered
    • 12.1.7 ADAPTIVE BIOTECHNOLOGIES
      • 12.1.7.1 Business overview
      • 12.1.7.2 Products offered
      • 12.1.7.3 Recent developments
        • 12.1.7.3.1 Deals
    • 12.1.8 ARCHERDX (INVITAE CORPORATION)
      • 12.1.8.1 Business overview
      • 12.1.8.2 Products offered
      • 12.1.8.3 Recent developments
        • 12.1.8.3.1 Product launches
        • 12.1.8.3.2 Deals
    • 12.1.9 BIO-RAD LABORATORIES, INC.
      • 12.1.9.1 Business overview
      • 12.1.9.2 Products offered
    • 12.1.10 NATERA, INC.
      • 12.1.10.1 Business overview
      • 12.1.10.2 Products offered
  • 12.2 OTHER PLAYERS
    • 12.2.1 OPKO HEALTH, INC.
    • 12.2.2 GENETRON HEALTH
    • 12.2.3 QUEST DIAGNOSTICS, INC.
    • 12.2.4 ASURAGEN, INC.
    • 12.2.5 INVIVOSCRIBE, INC.
    • 12.2.6 ARUP LABORATORIES INC.
    • 12.2.7 MISSION BIO, INC.
    • 12.2.8 CERGENTIS B.V.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 CUSTOMIZATION OPTIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 HEMATOLOGIC CANCER INCIDENCE, BY TYPE, 2023
  • TABLE 2 INCIDENCE OF HEMATOLOGIC CANCERS, BY COUNTRY, 2023 VS. 2030
  • TABLE 3 INDICATIVE PRICE OF MRD TESTING PRODUCTS, BY PRODUCT & REGION, 2022-2024
  • TABLE 4 LIST OF KEY PATENTS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
  • TABLE 5 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 6 EXPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2019-2023 (USD MILLION)
  • TABLE 7 MINIMAL RESIDUAL DISEASE TESTING MARKET: ROLE IN ECOSYSTEM
  • TABLE 8 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 9 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MRD TESTS (%)
  • TABLE 10 KEY BUYING CRITERIA FOR MRD TESTS, BY END USER
  • TABLE 11 CHINA: CLASSIFICATION OF MEDICAL DEVICES
  • TABLE 12 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA
  • TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF CONFERENCES AND EVENTS
  • TABLE 19 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 20 KEY ASSAY KITS & REAGENTS AVAILABLE IN MARKET
  • TABLE 21 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 22 KEY INSTRUMENTS AVAILABLE IN MARKET
  • TABLE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR INSTRUMENTS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR PCR, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 26 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NGS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 27 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR FLOW CYTOMETRY, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 28 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 29 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 30 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 31 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 32 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 33 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 34 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 37 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 38 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 39 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 40 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 41 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 42 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 43 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MYELOID LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 44 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 45 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 46 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 48 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 49 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 50 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER LEUKEMIAS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 52 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 53 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 54 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 55 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 56 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 57 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 58 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 59 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR NON-HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 61 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 62 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 63 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 64 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HODGKIN LYMPHOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 65 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 66 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 67 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR SOLID TUMORS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 69 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 70 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 71 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR MULTIPLE MYELOMA, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 73 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 75 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 77 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 78 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 79 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 80 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 81 MINIMAL RESIDUAL DISEASE TESTING MARKET FOR OTHER END USERS, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 82 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2022-2029 (USD MILLION)
  • TABLE 83 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 84 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 85 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 87 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 88 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 89 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 90 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 91 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 92 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 93 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 94 US: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 95 US: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 96 US: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 97 US: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 98 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 99 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 100 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 101 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 102 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 103 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 104 CANADA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 105 EUROPE: FORECAST OF LEUKEMIA CASES, BY COUNTRY, 2025 VS. 2030 VS. 2035
  • TABLE 106 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 107 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 108 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 109 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 110 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 111 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 112 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 113 EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 114 GERMANY: CANCER INCIDENCE, BY TYPE, 2022
  • TABLE 115 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 116 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 117 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 118 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 119 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 120 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 121 GERMANY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 122 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 123 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 124 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 125 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 126 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 127 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 128 UK: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 129 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 130 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 131 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 132 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 133 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 134 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 135 FRANCE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 136 ITALY: HEMATOLOGICAL CANCER INCIDENCE, BY TYPE, 2022
  • TABLE 137 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 138 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 139 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 140 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 141 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 142 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 143 ITALY: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 144 SPAIN: HEMATOLOGICAL CANCER INCIDENCE, BY TYPE, 2022
  • TABLE 145 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 146 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 147 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 148 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 149 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 150 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 151 SPAIN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 152 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 153 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 154 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 155 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 156 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 157 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 158 REST OF EUROPE: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 159 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY COUNTRY, 2022-2029 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 162 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 163 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 164 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 166 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 167 CHINA: HEMATOLOGICAL CANCER INCIDENCE, BY TYPE, 2022
  • TABLE 168 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 169 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 170 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 171 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 172 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 173 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 174 CHINA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 175 JAPAN: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2022
  • TABLE 176 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 177 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 178 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 179 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 180 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 181 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 182 JAPAN: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 183 INDIA: HEMATOLOGY CANCER INCIDENCE, BY TYPE, 2022
  • TABLE 184 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 185 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 186 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 187 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 188 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 189 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 190 INDIA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 191 REST OF ASIA PACIFIC: GERIATRIC POPULATION, BY COUNTRY, 2023
  • TABLE 192 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 193 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 194 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 195 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 196 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 197 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 198 REST OF ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 199 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 200 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 201 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 202 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 203 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 204 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 205 LATIN AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 206 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 207 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 208 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 209 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 210 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 211 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 212 MIDDLE EAST & AFRICA: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 213 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2022-2029 (USD MILLION)
  • TABLE 214 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2022-2029 (USD MILLION)
  • TABLE 215 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2022-2029 (USD MILLION)
  • TABLE 216 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR HEMATOLOGICAL MALIGNANCIES, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 217 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LEUKEMIA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 218 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET FOR LYMPHOMA, BY TYPE, 2022-2029 (USD MILLION)
  • TABLE 219 GCC COUNTRIES: MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2022-2029 (USD MILLION)
  • TABLE 220 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET
  • TABLE 221 MINIMAL RESIDUAL DISEASE TESTING MARKET: DEGREE OF COMPETITION
  • TABLE 222 MINIMAL RESIDUAL DISEASE TESTING MARKET: PRODUCT FOOTPRINT
  • TABLE 223 MINIMAL RESIDUAL DISEASE TESTING MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 224 MINIMAL RESIDUAL DISEASE TESTING MARKET: APPLICATION FOOTPRINT
  • TABLE 225 MINIMAL RESIDUAL DISEASE TESTING MARKET: REGION FOOTPRINT
  • TABLE 226 MINIMAL RESIDUAL DISEASE TESTING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 227 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY PRODUCT & TECHNOLOGY
  • TABLE 228 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY APPLICATION & END USER
  • TABLE 229 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY REGION
  • TABLE 230 MINIMAL RESIDUAL DISEASE TESTING MARKET, PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 231 MINIMAL RESIDUAL DISEASE TESTING MARKET, DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 232 F. HOFFMANN-LA ROCHE AG: COMPANY OVERVIEW
  • TABLE 233 F. HOFFMANN-LA ROCHE AG: PRODUCTS OFFERED
  • TABLE 234 F. HOFFMANN-LA ROCHE AG: PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 235 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY OVERVIEW
  • TABLE 236 LABORATORY CORPORATION OF AMERICA HOLDINGS: PRODUCTS OFFERED
  • TABLE 237 LABORATORY CORPORATION OF AMERICA HOLDINGS: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 238 GUARDANT HEALTH, INC.: COMPANY OVERVIEW
  • TABLE 239 GUARDANT HEALTH, INC.: PRODUCTS OFFERED
  • TABLE 240 GUARDANT HEALTH, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 241 GUARDANT HEALTH, INC.: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 242 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 243 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 244 SYSMEX CORPORATION: PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 245 NEOGENOMICS LABORATORIES: COMPANY OVERVIEW
  • TABLE 246 NEOGENOMICS LABORATORIES: PRODUCTS OFFERED
  • TABLE 247 NEOGENOMICS LABORATORIES: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 248 MOLECULARMD (A SUBSIDIARY OF ICON PLC): COMPANY OVERVIEW
  • TABLE 249 MOLECULARMD (A SUBSIDIARY OF ICON PLC): PRODUCTS OFFERED
  • TABLE 250 ADAPTIVE BIOTECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 251 ADAPTIVE BIOTECHNOLOGIES: PRODUCTS OFFERED
  • TABLE 252 ADAPTIVE BIOTECHNOLOGIES: DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 253 ARCHERDX (INVITAE CORPORATION): COMPANY OVERVIEW
  • TABLE 254 ARCHERDX (INVITAE CORPORATION): PRODUCTS OFFERED
  • TABLE 255 ARCHERDX (INVITAE CORPORATION): PRODUCT LAUNCHES, JANUARY 2021-NOVEMBER 2024
  • TABLE 256 ARCHERDX (INVITAE CORPORATION): DEALS, JANUARY 2021-NOVEMBER 2024
  • TABLE 257 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 258 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 259 NATERA, INC.: COMPANY OVERVIEW
  • TABLE 260 NATERA, INC.: PRODUCTS OFFERED
  • TABLE 261 OPKO HEALTH, INC.: COMPANY OVERVIEW
  • TABLE 262 GENETRON HEALTH: COMPANY OVERVIEW
  • TABLE 263 QUEST DIAGNOSTICS, INC.: COMPANY OVERVIEW
  • TABLE 264 ASURAGEN, INC.: COMPANY OVERVIEW
  • TABLE 265 INVIVOSCRIBE, INC.: COMPANY OVERVIEW
  • TABLE 266 ARUP LABORATORIES INC.: COMPANY OVERVIEW
  • TABLE 267 MISSION BIO, INC.: COMPANY OVERVIEW
  • TABLE 268 CERGENTIS B.V.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 MINIMAL RESIDUAL DISEASE TESTING MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 MINIMAL RESIDUAL DISEASE TESTING MARKET: RESEARCH DESIGN
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 5 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 6 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 7 MINIMAL RESIDUAL DISEASE TESTING MARKET: TOP-DOWN APPROACH
  • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • FIGURE 9 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY PRODUCT, 2024 VS. 2029 (USD MILLION)
  • FIGURE 10 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY APPLICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 MINIMAL RESIDUAL DISEASE TESTING MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 RISING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH DURING FORECAST PERIOD
  • FIGURE 15 ASSAY KITS & REAGENTS SEGMENT TO DOMINATE MARKET IN 2029
  • FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 17 HEMATOLOGICAL MALIGNANCIES WILL CONTINUE TO DOMINATE MARKET IN 2029
  • FIGURE 18 HOSPITALS & SPECIALTY CLINICS TO BE LARGEST END USERS OF MINIMAL RESIDUAL DISEASE TESTING
  • FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD
  • FIGURE 20 MINIMAL RESIDUAL DISEASE TESTING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 PATENT ANALYSIS FOR MINIMAL RESIDUAL DISEASE TESTING MARKET
  • FIGURE 22 VALUE CHAIN ANALYSIS: MAJOR VALUE ADDED DURING MANUFACTURING AND ASSEMBLY PHASES
  • FIGURE 23 MINIMAL RESIDUAL DISEASE TESTING MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 24 MINIMAL RESIDUAL DISEASE TESTING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 25 MINIMAL RESIDUAL DISEASE TESTING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 26 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF MRD TESTS
  • FIGURE 27 KEY BUYING CRITERIA FOR MINIMAL RESIDUAL DISEASE TESTING PRODUCTS
  • FIGURE 28 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 29 DEALS AND FUNDING IN MRD TESTING MARKET
  • FIGURE 30 NORTH AMERICA: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
  • FIGURE 31 ASIA PACIFIC: MINIMAL RESIDUAL DISEASE TESTING MARKET SNAPSHOT
  • FIGURE 32 REVENUE ANALYSIS OF KEY PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET (2019-2023)
  • FIGURE 33 MARKET SHARE ANALYSIS OF TOP PLAYERS IN MINIMAL RESIDUAL DISEASE TESTING MARKET (2023)
  • FIGURE 34 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 35 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY FOOTPRINT
  • FIGURE 36 MINIMAL RESIDUAL DISEASE TESTING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
  • FIGURE 37 EV/EBITDA OF KEY VENDORS
  • FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 39 BRAND COMPARISON FOR ASSAY KITS & REAGENTS
  • FIGURE 40 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2023)
  • FIGURE 41 LABORATORY CORPORATION OF AMERICA HOLDINGS: COMPANY SNAPSHOT (2023)
  • FIGURE 42 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 43 SYSMEX CORPORATION: COMPANY SNAPSHOT (2022)
  • FIGURE 44 MOLECULARMD (A SUBSIDIARY OF ICON PLC): COMPANY SNAPSHOT (2023)
  • FIGURE 45 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT (2023)
  • FIGURE 46 ARCHERDX (INVITAE CORPORATION): COMPANY SNAPSHOT (2022)
  • FIGURE 47 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 48 NATERA, INC.: COMPANY SNAPSHOT (2023)